Datapoint: J&J Scores Approval for First Twice-Yearly Schizophrenia Drug

The FDA last week approved Johnson & Johnson’s Invega Hafyera, a long-acting atypical antipsychotic, for the treatment of schizophrenia, expanding the drugmaker’s hold on the market. The drug is the first-ever twice-yearly injectable approved to treat the disease. First approved in 2006, J&J’s extended release Invega tablet currently holds covered or better status for 75% of all insured lives under the pharmacy benefit. Two other long-acting injectable forms of the drug, Invega Sustenna (77% covered or better) and Invega Trinza (58% covered or better) are also on the market.

SOURCE: MMIT Analytics, as of 9/1/21

0 Comments

AIS Health Staff

Related Posts

https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 24

Datapoint: Keytruda Scores Major Kidney Cancer Nod

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 23

Datapoint: Zing Health Acquires Lasso Healthcare

Read More
https://www.mmitnetwork.com/wp-content/uploads/2021/09/wordpress-featured-image-datapoints.jpg
November 22

Datapoint: Paramount Loses Ohio Medicaid Battle

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today